Epitan resumes sustained release trial
Tuesday, 06 July, 2004
Melbourne-based EpiTan (ASX:EPT) has resumed its trial of the sustained release implant for tanning drug Melanotan.
The trial is being conducted at Queensland's Clive Berghofer Cancer Research Centre with a new significantly smaller solid injectable. It will be used to determine the optimal dose for the final commercial formulation of Melanotan.
Epitan executive chairman Dr Wayne Millen said the new implant was able to be injected with a 16 gauge needle.
mRNA successfully delivered through blood–brain barrier
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...
Biological computer could revolutionise medical sciences
The CL1 is a commercial biological computer which fuses lab-cultivated neurons from human stem...
Genetic risk of schizophrenia impacts men and women differently
Men tend to present different clinical symptoms from women, poorer premorbid functioning and...
